ADITEC press release
Guildford, Surrey - 23 November 2015 - High quality vaccine research funded by the EUR 30 million FP7 High Impact Project on Advanced Immunization Technologies (ADITEC) is confirmed by the bibliometric analysis of the scientific papers produced by the project. This analysis, posted online today, demonstrates that the impressive number of publications is the direct result of the highly collaborative research done by ADITEC. The investments of the European Commission in the project have already had and will continue to have a substantial impact on the future of the vaccinology research in Europe and beyond, as well as on the development of new immunization technologies.
This report is the first ADITEC bibliometric analysis of which journals have published ADITEC research findings, how many times these papers are cited by other researchers (the ‘citation impact’), where the research is done and its collaborative nature.
ADITEC started at the end of 2011. In its first 4 years, 148 publications in 74 different peer-reviewed journals were produced. Key findings of the analysis include:
- 148 publications in 74 peer-reviewed journals
- the total Journal Impact Factor of all ADITEC publications is 1010
- 88% of papers were published in journals with impact factors in the top 25% their respective subject categories.
- average Journal Impact Factor of 7.21
- collectively these publications have been cited 1645 times
- 49% of all published research of ADITEC has resulted from international collaborations
- 82% of all ADITEC publications represent work done across sectors (academic, government, private, medical, corporate).
- 24% of papers involved several ADITEC project partners
- Scientists from 30 different countries were involved in authoring papers resulting from ADITEC sponsored research
The European Commission recognizes that ADITEC is a successful, highly innovative project. Its highly-regarded groups of investigators are advancing our understanding of the development of human immune responses after vaccination. Major strengths of ADITEC are its focus on head-to-head comparison of model antigens with adjuvants, and on the performance of clinical trials in both children and elderly.
The Project Coordinator, Dr. Rino Rappuoli of Sclavo Vaccines Association (SVA), points out that “Vaccination, the oldest and most impactful medical intervention, is also one of the most vibrant and innovative fields of our times. In ADITEC we have been able to bring together the leading European vaccinologists during a period of technological revolution. I strongly believe that the technologies developed during this period will have a great impact on the society of our century.”
The Scientific Coordinator of the project, Professor Donata Medaglini of the University of Siena and SVA, is very excited about the results so far. “From the start of the project we already had high expectations of this unique combination of research partners. Scientists from 42 institutions in 13 different countries work together in an unprecedented effort in the fast moving field of new immunization technologies. The excellence of ADITEC research is confirmed by the large number of highly cited collaborative publications in the most prestigious journals”. Other important results are expected in the coming year.
Read the complete bibliometric report
Note to the editor:
For more information, please contact Donata Medaglini, Scientific Coordinator, Medaglini@sclavo.org +39 0577 233307
ADITEC (Advanced Immunization Technologies, www.aditecproject.eu) is a collaborative research programme that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Scientists from 13 countries and 42 research institutions collaborate in the ADITEC project. ADITEC comprises some of the most competitive European research groups from universities, research institutions and biotech companies together with top US groups on systems biology and adjuvants. Different aspects of vaccination, from basic research and new technologies to clinical trials and public health, are covered.